Table 3.

Summary of adverse events^a

Adverse event	All grades	Grades 3/4
	Patients, n (%)
Edema peripheral	31 (38.8%)	0
Nausea	28 (35.0%)	2 (2.5%)
Fatigue	27 (33.8%)	0
Headache	26 (32.5%)	0
Pyrexia	25 (31.3%)	1 (1.3%)
Hypocalcaemia	19 (23.8%)	0
Hypophosphatemia	19 (23.8%)	8 (10.0%)
Constipation	18 (22.5%)	0
Anemia	17 (21.3%)	8 (10.0%)
Diarrhea	17 (21.3%)	0
Alanine aminotransferase increased	17 (21.3%)	1 (1.3%)
Lymphocyte count decreased	16 (20.0%)	16 (20.0%)
Hypoalbuminemia	16 (20.0%)	0
Hypokalemia	13 (16.3%)	2 (2.5%)
Hypertension	12 (15.0%)	6 (7.5%)
Platelet count decreased	9 (11.3%)	5 (6.3%)
Hyponatremia	9 (11.3%)	2 (2.5%)
White blood cell count decreased	8 (10.0%)	7 (8.8%)
Capillary leak syndrome	7 (8.8%)	2 (2.5%)
Upper respiratory infection	7 (8.8%)	2 (2.5%)
Hemolytic uremic syndrome	6 (7.5%)	4 (5.0%)
Neutrophil count decreased	6 (7.5%)	5 (6.3%)
Febrile neutropenia	5 (6.3%)	4 (5.0%)
Neutropenia	4 (5.0%)	4 (5.0%)
Hypoxia	4 (5.0%)	2 (2.5%)
Lung infection	3 (3.8%)	2 (2.5%)
Acute kidney injury	3 (3.8%)	2 (2.5%)
Erysipelas	2 (2.5%)	2 (2.5%)

^aAdverse events of any grade with an incidence of at least 20%, as well as events of grade 3 or grade 4 with an incidence of at least 2.5%